Immunomedics (IMMU) Receives US Patent 8,076,140 for Improved Cell Lines for Protein Therapeutic Manufacturing
Tweet
Share
E-mailGet Alerts IMMU Hot Sheet
Join SI Premium – FREE
Immunomedics, Inc. (Nasdaq: IMMU) today announced that it was awarded US patent 8,076,140, "Mammalian cell lines for increasing longevity and protein yield from a cell culture."
This patent covers improved cell lines of greater longevity, allowing increased production of recombinant proteins such as antibodies, antibody fragments, multispecific and multivalent antibodies, antibody fusion proteins, peptides, enzymes, growth factors, interleukins, interferons, erythropoietin, thrombopoietin, hormones, and vaccines. The patent provides coverage until 2025.
This patent covers improved cell lines of greater longevity, allowing increased production of recombinant proteins such as antibodies, antibody fragments, multispecific and multivalent antibodies, antibody fusion proteins, peptides, enzymes, growth factors, interleukins, interferons, erythropoietin, thrombopoietin, hormones, and vaccines. The patent provides coverage until 2025.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Kimbell Royalty closes $221.2M mineral rights acquisition
- Curvature Securities terminates ATM sales pact with Planet Green
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
